Enfusion, Inc. (NYSE:ENFN) Receives Average Rating of "Reduce" from Brokerages

Shares of Enfusion, Inc. (NYSE:ENFN - Get Free Report) have received an average recommendation of "Reduce" from the six analysts that are covering the firm, MarketBeat.com reports. Three analysts have rated the stock with a sell rating, one has assigned a hold rating and two have issued a buy rating on the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $10.25.

ENFN has been the subject of a number of recent research reports. Stifel Nicolaus increased their target price on Enfusion from $11.00 to $13.00 and gave the stock a "buy" rating in a report on Wednesday, December 18th. Piper Sandler increased their price objective on Enfusion from $10.00 to $11.50 and gave the stock a "neutral" rating in a research note on Monday, December 23rd.

Insider Activity at Enfusion

In related news, COO Neal Pawar sold 21,801 shares of Enfusion stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $10.03, for a total value of $218,664.03. Following the completion of the sale, the chief operating officer now directly owns 1,143,544 shares in the company, valued at $11,469,746.32. This trade represents a 1.87 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Oleg Movchan sold 2,771 shares of the business's stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $10.13, for a total value of $28,070.23. Following the sale, the chief executive officer now directly owns 526,702 shares of the company's stock, valued at $5,335,491.26. This represents a 0.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 56,404 shares of company stock valued at $580,130 over the last ninety days. 36.44% of the stock is owned by insiders.

Institutional Trading of Enfusion

A number of institutional investors have recently bought and sold shares of the business. TenCore Partners LP bought a new stake in shares of Enfusion in the 3rd quarter valued at about $3,938,000. Dimensional Fund Advisors LP increased its stake in Enfusion by 57.5% in the second quarter. Dimensional Fund Advisors LP now owns 524,142 shares of the company's stock valued at $4,466,000 after purchasing an additional 191,436 shares in the last quarter. JPMorgan Chase & Co. increased its stake in Enfusion by 612.4% in the third quarter. JPMorgan Chase & Co. now owns 208,022 shares of the company's stock valued at $1,974,000 after purchasing an additional 178,821 shares in the last quarter. Impax Asset Management Group plc boosted its position in shares of Enfusion by 25.4% during the third quarter. Impax Asset Management Group plc now owns 676,948 shares of the company's stock worth $6,424,000 after purchasing an additional 136,948 shares in the last quarter. Finally, Scalar Gauge Management LLC boosted its position in shares of Enfusion by 21.8% during the second quarter. Scalar Gauge Management LLC now owns 613,513 shares of the company's stock worth $5,227,000 after purchasing an additional 110,000 shares in the last quarter. Institutional investors and hedge funds own 81.05% of the company's stock.

Enfusion Stock Down 3.1 %

Enfusion stock traded down $0.32 on Friday, hitting $9.97. The company's stock had a trading volume of 351,791 shares, compared to its average volume of 403,182. The company has a fifty day moving average price of $10.11 and a 200-day moving average price of $9.20. The firm has a market cap of $1.28 billion, a P/E ratio of 249.31, a price-to-earnings-growth ratio of 3.98 and a beta of 0.95. Enfusion has a one year low of $7.52 and a one year high of $11.38.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.